Your browser doesn't support javascript.
loading
Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
Isaka, Yoshitaka; Hamano, Takayuki; Fujii, Hideki; Tsujimoto, Yoshihiro; Koiwa, Fumihiko; Sakaguchi, Yusuke; Tanaka, Ryoichi; Tomiyama, Noriyuki; Tatsugami, Fuminari; Teramukai, Satoshi.
Afiliação
  • Isaka Y; Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Hamano T; Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Fujii H; Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Tsujimoto Y; Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine.
  • Koiwa F; Division of Internal Medicine, Medical Corporation Aijinkai Inoue Hospital, Suita, Japan.
  • Sakaguchi Y; Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Tanaka R; Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Tomiyama N; Department of Radiology, Iwate Medical University School of Medicine, Shiwa, Japan.
  • Tatsugami F; Division of Dental Radiology, Department of Reconstructive Oral and Maxillofacial Surgery, Iwate Medical University School of Dentistry, Shiwa, Japan.
  • Teramukai S; Department of Radiology, Osaka University Graduate School of Medicine, Suita, Japan.
J Am Soc Nephrol ; 32(3): 723-735, 2021 03.
Article em En | MEDLINE | ID: mdl-33547218
ABSTRACT

BACKGROUND:

In patients on maintenance dialysis, cardiovascular mortality risk is remarkably high, which can be partly explained by severe coronary artery calcification (CAC). Hyperphosphatemia has been reported to be associated with the severity of CAC. However, the optimal phosphate range in patients on dialysis remains unknown. This study was planned to compare the effects on CAC progression of two types of noncalcium-based phosphate binders and of two different phosphate target ranges.

METHODS:

We conducted a randomized, open-label, multicenter, interventional trial with a two by two factorial design. A total of 160 adults on dialysis were enrolled and randomized to the sucroferric oxyhydroxide or lanthanum carbonate group, with the aim of reducing serum phosphate to two target levels (3.5-4.5 mg/dl in the strict group and 5.0-6.0 mg/dl in the standard group). The primary end point was percentage change in CAC scores during the 12-month treatment.

RESULTS:

The full analysis set included 115 patients. We observed no significant difference in percentage change in CAC scores between the lanthanum carbonate group and the sucroferric oxyhydroxide group. On the other hand, percentage change in CAC scores in the strict group (median of 8.52; interquartile range, -1.0-23.9) was significantly lower than that in the standard group (median of 21.8; interquartile range, 10.0-36.1; P=0.006). This effect was pronounced in older (aged 65-74 years) versus younger (aged 20-64 years) participants (P value for interaction =0.003). We observed a similar finding for the absolute change in CAC scores.

CONCLUSIONS:

Further study with a larger sample size is needed, but strict phosphate control shows promise for delaying progression of CAC in patients undergoing maintenance hemodialysis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER Evaluate the New Phosphate Iron-Based Binder Sucroferric Oxyhydroxide in Dialysis Patients with the Goal of Advancing the Practice of EBM (EPISODE), jRCTs051180048.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosfatos / Doença da Artéria Coronariana / Calcinose / Diálise Renal Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosfatos / Doença da Artéria Coronariana / Calcinose / Diálise Renal Idioma: En Ano de publicação: 2021 Tipo de documento: Article